Impaired host immunity is thought to play a role in the pathogenesis and progression of lymphoma. Expression of the negative T cell regulator PD-L1 appears to facilitate immune tolerance of various carcinomas. Here, we describe the spectrum of expression of PD-L1 among non-Hodgkin lymphomas and evaluate its functional activity in suppressing T cell responses. In vitro experiments using established cell lines and primary lymphoma specimens demonstrate that both T cell and B cell lymphomas express biologically active PD-L1, and that suppression of tumor-associated T cells can be reversed by PD-L1 blockade. Among diffuse large B cell lymphomas, the most common non-Hodgkin lymphoma in adults, we found that PD-L1 is expressed only in the non-germinal center subtype, which carries a poorer prognosis and frequently recurs after conventional chemoimmunotherapy. Our results suggest that targeting PD-L1 may be an effective anti-lymphoma immunotherapy for certain histologic subtypes. 
Translational statement
Impaired host immunity is thought to play a role in the pathogenesis and progression of lymphoma. Expression of the negative T cell regulator PD-L1 appears to facilitate immune tolerance of various carcinomas. Here, we describe the spectrum of expression of PD-L1 among non-Hodgkin lymphomas and evaluate its functional activity in suppressing T cell responses. In vitro experiments using established cell lines and primary lymphoma specimens demonstrate that both T cell and B cell lymphomas express biologically active PD-L1, and that suppression of tumor-associated T cells can be reversed by PD-L1 blockade. Among diffuse large B cell lymphomas, the most common non-Hodgkin lymphoma in adults, we found that PD-L1 is expressed only in the non-germinal center subtype, which carries a poorer prognosis and frequently recurs after conventional chemoimmunotherapy. Our results suggest that targeting Introduction PD-1, a member of the CD28 family, is an inhibitory receptor expressed on the surface of T cells which functions to physiologically limit T cell activation and proliferation. 1 Its ligand, PD-L1 (B7-H1/CD274), is expressed on antigen presenting cells. Binding of PD-L1 to its receptor inhibits T cell activation and counterbalances T cell stimulatory signals, such as the binding of B7 to CD28.
Dysregulation of the PD-1/PD-L1 pathway has been implicated in a wide variety of diseases. Impairment of PD-1/PD-L1 signaling can lead to autoimmune disease in murine systems. 2, 3 In humans, several single nucleotide polymorphisms in PD-1 have been associated with an increased risk of rheumatological disease. 4 Conversely, upregulation of PD-1 signaling is associated with the persistence of chronic infections, including HIV, 5, 6 Helicobacter pylori, 7 and schistosomiasis. 8 PD-L1 is not expressed by normal epithelial tissues, but it is aberrantly expressed on a wide array of human cancers. 9 In this context, PD-L1 may promote cancer progression by disabling the host anti-tumor response. Its expression on tumor cells has been associated with poorer prognosis in renal cell carcinoma, [10] [11] [12] breast cancer, 13 Wilms tumor, 14 pancreatic cancer, 15 ovarian cancer, 16 urothelial cancer, 17 gastric cancer, 18 esophageal cancer, 19 and hepatocellular carcinoma. 20 In murine systems, melanoma cells engineered to express PD-L1 are resistant to cytotoxic T lymphocyte (CTL)-mediated lysis and exhibit more aggressive tumor growth than wild-type melanoma. 21 Moreover, melanoma cells expressing PD-L1 can induce apoptosis in tumor-specific CTLs. 23 Another series reported that PD-L1 was expressed in 4 of 14 diffuse large B cell lymphomas (DLBCL), 0 of 9 T cell lymphomas, and 8 of 13 classic Hodgkin lymphoma (HL) cases. 24 In this report, we describe the pattern of expression of PD-L1 in a large series of primary human lymphoma specimens (n=110) and NHL cell lines (n=34). Using both cell lines and primary tumor specimens, we demonstrate that PD-L1 expressed on tumor cells is immunologically active in suppressing the activation of tumor-associated T cells. These results suggest PD-L1 blockade as a potentially useful strategy for lymphoma immunotherapy. For formalin-fixed specimens, histologic sections from paraffin-embedded tissue blocks were subjected to heat-induced epitope retrieval using a steamer at 95˚C for 25 minutes in 0.01 M citrate buffer, pH 6.0 (for PD-L1), or at 115˚C for 3 minutes in 0.1 mM EDTA pH 8.0 for CD10, BCL6 and MUM1. Sections were incubated with mouse mAbs to CD10 (Vector laboratories, Burlingame, CA), BCL6 (DAKO), and MUM1 (DAKO), followed by antibody localization using the DakoCytomation Envision + System-HRP-labeled polymer (DAKO).
After a 10 minute incubation with DAB, sections were counterstained with hematoxylin.
Staining for PD-L1 in paraffin sections was performed using a mAb (clone 5H1, provided by Dr.
Lieping Chen, Johns Hopkins University) at BioPillar Laboratories (Monmouth Junction, New Jersey) using previously described methods, 11 or using a polyclonal rabbit antiserum (Lifespan Biosciences, Seattle, WA), followed by DAKO DakoCytomation Envision + labeled polymer HRP-anti-rabbit detection.
Allogeneic T cell proliferation assays
T cells were enriched from whole blood obtained from healthy donors who gave informed consent using the RosetteSep 
Cytokine analyses
For allogeneic experiments, supernatants from co-cultures of Karpas 299 cells and healthy donor T cells, as described above under allogeneic T cell proliferation assays, were collected after 4 days incubation and analyzed for IFN-γ by enzyme-linked immunosorbent assay (ELISA; R&D Systems). 96-well Maxisorp plates (Nunc) were coated with mouse anti-human IFN-γ antibody, then washed and blocked with 1% BSA in PBS for 1 hour. Supernatants were added and incubated for 2 hours, followed by biotinylated goat anti-human IFN-γ antibody (50 ng/ml). Detection was performed using streptavidin-conjugated HRP and hydrogen peroxidetetramethylbenzidine substrate, and absorbance determined at 450 nm/570 nm with a SPECTRAmax Plus 384 microplate reader (Molecular Devices, Sunnyvale, CA). Recombinant human IFN-γ was used to generate a standard curve.
For autologous tumor cell-T cell co-cultures, cryopreserved LC-96 and RS-27 primary tumor specimens were thawed at 37˚C, washed twice with warm RPMI complete medium, and 2- 
Results

PD-L1 is widely expressed by ALCL but uncommonly among B cell non-Hodgkin lymphoma cell lines
We screened a large panel of human lymphoma cell lines for PD-L1 expression using flow cytometry ( Table 1) Table 1 ). In addition, all cell lines were screened for PD-1 and PD-L2 expression. Only Jurkat cells expressed PD-1 (data not shown), and no cell line expressed PD-L2.
We then attempted to induce PD-L1 expression in B cell lymphoma lines that did not constitutively express it, as stimulation of some tumor cells with IFN-γ can induce PD-L1 expression. 9, 27 Ramos, Daudi, SU-DHL-4, and SU-DHL-6 were incubated with IFN-γ or CpG Therefore, we asked whether IL-6 and IL-10 stimulation of NHL lines could upregulate PD-L1.
Daudi, Ramos, SU-DHL-4, SU-DHL-6, OCI-Ly-3, and HBL-1 cells were cultured with IL-6, IL-10, or both at 50 ng/ml for 24 to 72 hours, but none showed significant increase in PD-L1 expression (data not shown). Thus, PD-L1 expression is not readily altered in cultured lymphoma cells by exogenous cytokines.
PD-L1 is expressed by a subset of primary human diffuse large B cell lymphomas
We next tested 68 lymphoma tissue specimens for expression of PD-L1 (Table 2A-B) . We next performed immunohistochemistry for PD-L1 expression in a separate set of 42 formalin-fixed, paraffin-embedded lymphoma specimens (Table 2C) , which required a different mAb (5H1), previously used to stain PD-L1 in paraffin sections. 10, 30 Cases were considered positive when the majority of tumor cells stained for PD-L1. All Comparative results of the frozen and paraffin DLBCL series are shown in Table 2D .
Of note, we also stained 91 formalin-fixed, paraffin-embedded lymphoma specimens using a polyclonal rabbit anti-PD-L1 antiserum (Lifespan Biosciences).
Using this methodology, 31 18 of 22 (82%) DLBCLs expressed PD-L1 (data not shown). Because of discordance between paraffin and frozen section results, we tested the polyclonal anti-PD-L1
antibody on cell pellets of several PD-L1-negative B cell lines and a Daudi lymphoma xenograft.
As several of these negative controls stained positive, we concluded that this antibody was unreliable for detecting PD-L1 expression in lymphomas.
PD-L1 expressed by ALCL inhibits the proliferation and cytokine secretion of allogeneic T cells
We next asked whether PD-L1 expressed by lymphoma cells was biologically active in attenuating host immune responses. Because PD-L1 was strongly expressed in both ALCL cell lines and tumor specimens, we chose this as our initial in vitro model. We hypothesized that To further characterize the T cell response induced by PD-L1 blockade, we quantitated the secretion of 16 cytokines using multiplex ELISA. First, we measured the cytokines present in cell-free ascites fluid, which would reflect the tumor environment in situ (Supplemental Figure 2A) . Interestingly, the fluid contained high levels of IL-6, as well as IL-10, and SDF-1β.
We next surveyed cytokines in spent culture media from the established LC-96 cell line (Supplemental Figure 2B) , to discern which might be products of tumor cells themselves. High levels of IL-8, IL-10, and SDF-1β were observed, indicating these as likely products of primary tumor cells in vivo.
Next, primary ascites cells were incubated with or without PHA and anti-PD-L1 antibody, and the cytokine profile determined (Supplemental Figure 2C) . Without PHA, most cytokines were secreted at low levels. However, the addition of anti-PD-L1 resulted in increased secretion of IL-6, IL-8, TNF-α, and MIP-1α compared to control antibody or media alone. The 
PD-L1 expression may be lost or attenuated during serial in vitro passage of lymphoma cells
In deriving the new RS-27 B cell lymphoma line, we discovered that expression of PD-L1 can be lost during in vitro culture ( Figure 4C 
While virtually all primary melanomas express PD-L1, most melanoma cell lines do not. although the same association is not seen in DLBCL. 40, 41 Thus, further studies examining the relationships between lymphoma-associated macrophages, PD-L1 expression, and clinical outcome are warranted. For such studies it will be important to utilize the monoclonal antibodies M1H1 or 5H1. In our experience, the polyclonal anti-PD-L1 antisera used by Marzec et al blockade. 42 Similarly, Neelapu et al found that PD-1 was markedly upregulated on tumorderived and peripheral blood T cells in FL in association with impaired Th1 cytokine secretion. 43 Antibody blockade of PD-1 improved proliferation of tumor-derived T cells and promoted the activation of NK cells. 44 As in other series, we found near uniform expression of PD-L1 in ALCL, a rare but clinically distinct T cell neoplasm. Nonetheless, PD-L1 is not a feature of all peripheral T cell lymphomas. Wilcox and colleagues 30 found that PD-L1 was expressed by T cell lymphoma tumor cells in only a minority of cases, yet often expressed by tumor-associated stromal histiocytes, just as we observed in DLBCL. Our report adds to these findings in demonstrating (Figures 2-4 and Supplemental Figures 2-3 ).
In our cultures of primary ALCL ascites cells containing autologous T cells, PD-L1
blockade enhanced the production of IFN-γ, as well as GM-CSF, IL-1, IL-6, IL-8, TNF-α, IL-13, and MIP-1α. We also noted that the ascites fluid representing the tumor microenvironment of this case contained high levels of IL-6, IL-10, and SDF-1β, while the established LC-96 cell line secreted these same cytokines, plus IL-8. These cytokines likely play roles in the pathogenesis and clinical manifestations of ALCL, having been detected in ALCL and other lymphomas. [45] [46] [47] [48] Intriguingly, SDF-1 (CXCL12) is associated with cancer metastasis 49 and angiogenesis, 41 and since most ALCL express the SDF-1 receptor CXCR4, 50 this suggests a possible autocrine feedback loop in this lymphoma subtype.
In conclusion, the current work adds to a growing body of literature documenting the important role of PD-1/PD-L1 signaling in the pathogenesis of NHL. PD-L1 is highly expressed in ALCL, HL, and some poor-prognosis DLBCL of the ABC/non-GCB subtype, where it acts to negatively regulate adjacent T cells. Targeting the PD-1/PD-L1 pathway using antagonistic monoclonal antibodies may thus be an attractive approach to lymphoma immunotherapy. Table 1 . Expression of PD-L1 among 34 human lymphoma cell lines Expression of PD-L1 and PD-L2 was measured by flow cytometry. "++" indicates ≥ 2 logs mean fluorescence intensity (MFI) above isotype control; "+" indicates < 2 logs MFI above control. Abbreviations: ALCL, anaplastic large cell lymphoma; T-ALL, precursor T acute lymphoblastic leukemia; DLBCL, diffuse large B cell lymphoma; GCB, germinal center B subtype; ABC, activated B cell subtype.
Cell line
Lymphoma subtype PD-L1 PD-L2 from human serum
B cell lines
Daudi Burkitt - - Raji Burkitt - - Ramos Burkitt - - BJA-B Burkitt - - MC116 Burkitt - - NU-DHL-1 DLBCL (GCB) - - OCI-Ly-2 DLBCL (GCB) - - OCI-Ly-7 DLBCL (GCB) - - OCI-Ly-19 DLBCL (GCB) - - SU-DHL-4 DLBCL (GCB) - - SU-DHL-6 DLBCL (GCB) - - SU-DHL-2 DLBCL (ABC) - - U2932 DLBCL (ABC) - - OCI-Ly-3 DLBCL (ABC) - - OCI-Ly-10 DLBCL (ABC) ++ - HBL-1 DLBCL (ABC) + - RC-K8 DLBCL (NF-κB + ) + - SU-DHL-5 DLBCL - - SU-DHL-7 DLBCL - - SU-DHL-8 DLBCL - - SU-DHL-9 DLBCL - - SU-DHL-10 DLBCL - - SU-DHL-16 DLBCL - - USC-DHL-1 DLBCL - - Granta-519 Mantle cell - - JeKo-1 Mantle cell - - REC-1 Mantle cell - - BCBL-1 1° effusion - -
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